基本信息
浏览量:55
职业迁徙
个人简介
In his role as executive vice chancellor, Perlmutter is responsible for universitywide commercialization efforts, focusing on developing strategic industry partnerships in order to shepherd more of the university’s world-class research through the drug-development process. The goal is to translate as much laboratory research as possible into real treatments that will recognizably and concretely improve human health.
As a physician-scientist, Perlmutter is internationally recognized for his research on alpha-1 antitrypsin deficiency (ATD), a genetic disorder in which accumulations of a misfolded protein can cause severe liver damage. His work has led to advances in the understanding of how cells dispose of misfolded proteins that cause cellular dysfunction as well as the development of a pipeline of ATD drugs that could eliminate the need for liver transplantation in those with the disorder. Since drugs in this pipeline target and enhance autophagy, a cellular degradation pathway that is critical for the functioning of all cells and declines with age, they also represent exciting candidates for prevention of cognitive decline and other degenerative diseases of aging. Through his research, his team has recently discovered a lead candidate drug that targets a natural cellular pathway in a way that may slow, or even prevent, age-dependent degenerative diseases of the liver, heart and nervous system.
As a physician-scientist, Perlmutter is internationally recognized for his research on alpha-1 antitrypsin deficiency (ATD), a genetic disorder in which accumulations of a misfolded protein can cause severe liver damage. His work has led to advances in the understanding of how cells dispose of misfolded proteins that cause cellular dysfunction as well as the development of a pipeline of ATD drugs that could eliminate the need for liver transplantation in those with the disorder. Since drugs in this pipeline target and enhance autophagy, a cellular degradation pathway that is critical for the functioning of all cells and declines with age, they also represent exciting candidates for prevention of cognitive decline and other degenerative diseases of aging. Through his research, his team has recently discovered a lead candidate drug that targets a natural cellular pathway in a way that may slow, or even prevent, age-dependent degenerative diseases of the liver, heart and nervous system.
研究兴趣
论文共 193 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Jie Li, Francesca Moretti, Tunda Hidvegi,Sanja Sviben,James A J Fitzpatrick, Hemalatha Sundaramoorthi, Stephen C Pak, Gary A Silverman,Britta Knapp,Ireos Filipuzzi,John Alford,John Reece-Hoyes,
Cellular and molecular gastroenterology and hepatologyno. 6 (2024): 1007-1024
Hepatology (Baltimore, Md.) (2024)
Jie Li, Francesca Moretti,Tunda Hidvegi,Sanja Sviben,James A.J. Fitzpatrick,Hemalatha Sundaramoorthi, Stephen C. Pak,Gary A. Silverman,Britta Knapp,Ireos Filipuzzi,John Alford,John Reece-Hoyes,
Cellular and Molecular Gastroenterology and Hepatologyno. 6 (2024): 1007-1024
引用0浏览0引用
0
0
Seong Won Lee,Young Mi Oh,Matheus B. Victor, Yan Yang, Shawei Chen, Ilya Strunilin,Sonika Dahiya,Roland E. Dolle, Stephen C. Pak,Gary A. Silverman,David H. Perlmutter,Andrew S. Yoo
Nature Agingno. 1 (2024): 95-109
Hepatology communicationsno. 3 (2023): e0070-e0070
Research square (2023)
Reference Module in Life Sciences (2022)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn